Sartorius AG

Sartorius AG
Name	Sartorius AG
Foundation	0 1870
Founder	Florenz Sartorius
Location	Göttingen, Germany
Key people	Joachim Kreuzburg (CEO)
Industry	Laboratory equipment, Biotechnology
Products	Laboratory balances, Filtration systems, Fermentation technology, Cell culture media
Revenue	▲ €4.5 billion (2023)
Num employees	16,000 (2023)
Homepage	https://www.sartorius.com

Sartorius AG is a leading international partner to the life sciences and bioprocessing industries. Headquartered in Göttingen, Germany, the company provides essential equipment and consumables for research and development and manufacturing processes in pharmaceuticals and biotechnology. With a history dating to 1870, it has evolved from a manufacturer of precision scales into a key player in biopharmaceutical production, operating globally with a significant presence in Europe, North America, and Asia.

History

The company was founded in 1870 by Florenz Sartorius in the university town of Göttingen, initially producing short-beam analytical balances for scientific use. Its early growth was closely tied to the renowned University of Göttingen and pioneering researchers like Walther Nernst and Otto Hahn. Following World War II, under the leadership of Horst Sartorius, the firm expanded its portfolio into membrane filtration technology during the 1960s, a strategic move that laid the foundation for its modern business. A major corporate restructuring occurred in 1990, separating the mechanical engineering division, which later became Sartorius Weighing Technology, and focusing the core company on biotechnology. The pivotal acquisition of the B. Braun biotech division in 2007 dramatically expanded its capabilities in fermentation and cell culture, cementing its role in bioprocess solutions.

Products and services

Sartorius operates through two main segments: Bioprocess Solutions and Laboratory Products & Services. The Bioprocess Solutions division offers integrated systems for biopharmaceutical manufacturing, including single-use bioreactors, fermenters, and filtration systems used in the production of monoclonal antibodies and vaccines. The Laboratory Products & Services division provides essential tools for research laboratories, such as laboratory balances, pipettes, cell analysis instruments, and purified water systems. Key technologies across both segments include advanced chromatography systems, microcarrier-based cell culture, and sophisticated data analytics software for process optimization.

Corporate structure

Sartorius AG is the parent company of the Sartorius Group, which is publicly listed on the Frankfurt Stock Exchange and part of the DAX index. The group is divided into two major operating subsidiaries: Sartorius Stedim Biotech, headquartered in Aubagne, France, which focuses on bioprocess solutions, and Sartorius Lab Instruments, based in Göttingen. The company maintains a decentralized operational model with over 60 production and sales sites worldwide, including major facilities in Ann Arbor, Bois-Colombes, and Shanghai. Governance is overseen by an Executive Board led by CEO Joachim Kreuzburg and a Supervisory Board chaired by Lothar Kappich.

Financial performance

The company has demonstrated strong and consistent growth, particularly driven by demand in the biopharmaceutical sector. For the 2023 fiscal year, Sartorius reported record sales of approximately €4.5 billion, with its Bioprocess Solutions segment contributing the majority of revenue. This performance reflects sustained high investment in research and development by its customers, including major pharmaceutical companies like Pfizer and Roche. The company's profitability, measured by underlying EBITDA margin, has remained robust, enabling significant reinvestment into capital expenditures and strategic acquisitions to fuel future expansion.

Acquisitions and partnerships

Sartorius has pursued an aggressive growth strategy through targeted acquisitions to broaden its technological portfolio and geographic reach. Major transactions include the purchase of Cellca and Biological Industries to strengthen its cell culture media business, and the acquisition of Novasep's chromatography division. In 2022, it completed the landmark acquisition of the purification and fluid management businesses from Danaher Corporation, a deal that significantly expanded its bioprocess capabilities. The company also maintains numerous research collaborations with academic institutions such as the Massachusetts Institute of Technology and industry partnerships within the International Society for Pharmaceutical Engineering.

Sustainability and social responsibility

The company has integrated environmental, social, and governance criteria into its core strategy, with published targets aligned with the Paris Agreement to reduce greenhouse gas emissions. Key initiatives include increasing energy efficiency at its plants, developing more sustainable single-use technologies, and reducing water consumption. Its social responsibility programs focus on employee development, diversity and inclusion, and supporting STEM education through partnerships with organizations like Jugend forscht. Sartorius's corporate citizenship efforts also involve contributions to local communities near its major sites and support for global health initiatives.

Category:Companies listed on the Frankfurt Stock Exchange Category:German medical equipment companies Category:Manufacturing companies established in 1870